product summary
Loading...
company name :
Bio-Rad
other brands :
Biogenesis, Serotec, AbD Serotec, Oxford Biotechnology
product type :
protein
product name :
Recombinant Human VEGF
catalog :
PHP091
quantity :
10 µg
price :
391 USD
more info or order :
product information
Entity Type :
Recombinant Protein
Entity Category :
Antigens and Lysates
ProductCode :
PHP091
Description :
Recombinant Human VEGF
Specificity :
VEGF
TargetSpecies :
Human
Format :
Rec. Protein
Applications :
E,WB,FN
ApplicationTypes :
ELISA,Western Blotting,Functional Assays
Quantity :
10 µg
Quantity Value :
10
Quantity Type :
µg
Uniprot Accessions :
P15692
Gene :
VEGFA
GeneID URL :
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=7422
Entity Formats :
Rec. Protein
UNSPSC :
12352202
Concentration :
0.1 mg/ml after reconstitution
Product Form :
Purified recombinant protein expressed in E. coli - lyophilized
PriceGBP :
265
PriceEUR :
274
PriceUSD :
391 USD
PriceCHF :
298
PriceSEK :
2987
PriceNOK :
3001
PriceDKK :
2043
more info or order :
company information
Bio-Rad
Endeavour House, Langford Business Park
Langford Lane, Kidlington
OXON, OX5 1GE
antibody_sales_uk@bio-rad.com
https://www.bio-rad-antibodies.com
1 800 265 7376 (North America)
44 (0)1865 852 700 (Rest of World)
headquarters: UK
Bio-Rad is one of the world's leading antibody manufacturers, offering over 12,000 antibodies and related reagents for a focused range of research areas such as immunology, cancer, veterinary research and cell biology through its antibody experts formerly known as AbD Serotec.
The range includes apoptosis kits, autophagy reagents, CD markers, epitope tag antibodies, immunology antibodies, neuroscience antibodies, and veterinary reagents.
Bio-Rad has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom as well as ISO 9001 certified facilities in Germany and the United States.
Our expertise extends to traditional and recombinant antibody generation and production services. Our custom generation service delivers antibodies in as little as 8 weeks with greater than 90% success. The in vitro technology enables selection of antibodies to challenging targets, long term consistent supply, and provision of the antibody sequence.
At Bio-Rad we are committed to your success when using our antibodies and we focus on providing the technology, products and all the supporting information you need to excel in your research.